The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKakuzi Regulatory News (KAKU)

Share Price Information for Kakuzi (KAKU)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 92.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 92.50
High: 0.00
Low: 0.00
Prev. Close: 92.50
KAKU Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Annual Financial Report

20 Mar 2024 08:27

RNS Number : 5853H
Kakuzi Ld
20 March 2024
 

 

KAKUZI PLC

 

 

ANNOUNCEMENT OF GROUP RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023

 
  

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

 

 

 

 

 

31 December 2023

 

31 December 2022

 

 

 

 

 

Shs'000

 

Shs'000

 

 

 

Sales

5,401,468

4,434,211

 

Profit before fair value gain in non-current biological assets and income tax

537,174

1,108,065

  Fair value gain in non-current biological assets

126,808

113,559

 

Profit before income tax

663,982

1,221,624

Income tax expense

(210,465

)

(375,820

)

Profit for the year

453,517

845,804

  Other Comprehensive Income:

Items that are not reclassified to profit or loss:

Remeasurement of post-employment benefit obligations (net of tax)

2,114

(5,176

)

Total comprehensive income

455,631

840,628

 

Shs

 

Shs

 

 

Earnings per share (Shs):

 

 

 

 

 

Basic and diluted earnings per ordinary share

23.14

43.15

  

Condensed Consolidated Statement of Financial Position

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

31 December 2023

 

31 December 2022

 

 

 

 

 

 

 

 

Shs'000

 

Shs'000

 

EQUITY

Share capital

98,000

98,000

Other reserves

34,929

32,815

Retained earnings

5,330,753

5,347,636

Proposed dividends

470,400

470,400

Total equity

5,934,082

5,948,851

Non-current liabilities

1,299,213

1,187,337

7,233,295

7,136,188

REPRESENTED BY

Non-current assets

4,055,135

4,089,669

Current assets excluding cash and cash balances

2,152,846

1,983,022

Cash and bank balances

1,408,131

1,408,744

Current liabilities

(382,817

)

(345,247

)

Net current assets

3,178,160

3,046,519

7,233,295

7,136,188

  

Condensed Consolidated Statement of Cash flows

 

 

 

 

 

31 December 2023

 

31 December 2022

 

 

 

 

 

Shs'000

 

Shs'000

 

 

 

Cash and cash equivalents at the beginning of the year

1,408,744

1,656,219

 

Net cash generated from operating activities

649,292

382,426

Net cash used in investing activities

(294,162

)

(281,012

)

Net cash used in financing activities

(470,400

)

(431,201

)

Net decrease in cash and cash equivalents

(115,270

)

(329,787

)

Net exchange gains on foreign currency cash & cash equivalent

114,657

82,312

Cash and cash equivalents at the end of the year

1,408,131

1,408,744

  

Condensed Consolidated Statement of Changes in Equity

 

 

 

 

 

 

Share

capital

 

Other reserves

 

Retained earnings

 

Proposed dividends

 

Total

Equity

 

 

Shs'000

 

Shs'000

 

Shs'000

 

Shs'000

 

Shs'000

 

 

 

 

 

 

 

 

 

 

 

 

On 1.1.2023

98,000

32,815

5,347,636

470,400

5,948,851

Profit for the year

-

-

453,517

-

453,517

Other comprehensive income

-

2,114

-

-

2,114

Dividends - final paid for 2022

-

-

-

(470,400

)

(470,400

)

- proposed for 2023

-

-

(470,400

)

470,400

-

 

On 31.12.2023

98,000

34,929

5,330,753

470,400

5,934,082

 

OVERVIEW:

 

Your Company recorded a pre-tax profit of Ksh 664 Million (2022: Ksh 1,221.6 Million). The pre-tax profit drop is mainly attributed to a Ksh 354 Million pre-tax loss from our macadamia operations (2022: Ksh 635 Million Profit). However, the avocado operations performed well, recording a pre-tax profit of Ksh1.4 Billion (2022: Ksh 0.8 Billion).

 

DIVIDEND:

 

Your Board recommends a dividend per share of Shs 24.00 compared to Shs 24.00 per share in 2022. The dividend shall be paid on or about 15 June 2024 to the shareholders on the members' register at the close of business on Friday, 31 May 2024.

 

ANNUAL GENERAL MEETING:

 

The Annual General Meeting of the Company will be held in the Ballroom at Nairobi Serena Hotel, Nairobi on Tuesday, 14th May 2024 at 12.00 Noon

 

BY ORDER OF THE BOARD

 

NICHOLAS NG'ANG'A

CHAIRMAN

19 MARCH 2024

 
 

  INDEPENDENT AUDITORS' REPORT ON THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS TO THE SHAREHOLDERS OF KAKUZI PLC

Opinion

The accompanying condensed consolidated financial statements of Kakuzi Plc and its subsidiaries (the "Group"), which comprise the condensed consolidated statement of financial position as at 31 December 2023, and the condensed consolidated statement of profit or loss and other comprehensive income, the condensed consolidated statement of changes in equity and the condensed consolidated statement of cash flows for the year then ended, are derived from the audited financial statements of the Group for the year ended 31 December 2023.

In our opinion, the accompanying condensed consolidated financial statements are consistent, in all material respects, with the audited financial statements of the Group, in accordance with the requirements of the Capital Markets (Securities) (Public Offers, Listings and Disclosures) Regulation, 2002 (''the Regulations'') as applicable to summary financial statements

?Condensed consolidated financial Statements

The condensed consolidated financial statements do not contain all the disclosures required by the International Financial Reporting Standards as applicable to annual financial statements. Reading the condensed consolidated financial statements and the auditors' report thereon, therefore, is not a substitute for reading the audited financial statements of the Group and the auditors' report thereon.

The audited financial statements and our report thereon

We expressed an unmodified audit opinion on the audited financial statements in our report dated 19 March 2024. That report also includes the communication of a key audit matter related to measurement of biological assets. Key audit matters are those matters that in our professional judgement were of most significance in our audit of the financial statements of the current period.

Auditors' responsibility

Our responsibility is to express an opinion on whether the condensed consolidated financial statements are consistent, in all material respects, with the audited financial statements based on our procedures, which were conducted in accordance with International Standard on Auditing (ISA) 810 (Revised), Engagements to Report on Summary Financial Statements.

The engagement partner responsible for the audit resulting in this independent auditor's report is CPA Fredrick Okwiri, Practicing Certificate No. 169

?For and on behalf of Deloitte & Touche LLP

Certified Public Accountants

Deloitte Place,

Waiyaki Way, Muthangari

P.O Box 40092 - 00100, Nairobi

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FR FIFFTVRIIFIS
12
Date   Source Headline
20th Mar 20248:27 amRNSAnnual Financial Report
6th Dec 20237:00 amRNSProfit Warning Announcement
25th Aug 20237:00 amRNSHalf-year Report
3rd Apr 20237:00 amRNSDirectorate Change
22nd Mar 20237:00 amRNSAnnual Financial Report
19th Aug 20227:00 amRNSHalf-year Report
23rd Mar 20227:00 amRNSAnnual Financial Report
6th Jan 20227:00 amRNS2021 PROFIT WARNING ANNOUNCEMENT
18th Aug 20217:00 amRNSHalf-year Report
22nd Mar 20217:00 amRNSAnnual Financial Report - Replacement
19th Mar 20217:00 amRNSAnnual Financial Report
2nd Nov 20207:00 amRNSDirectorate Change
19th Aug 20207:00 amRNSHalf-year Report
26th May 20207:00 amRNSAGM Statement
9th Apr 20207:00 amRNSDividend Declaration
20th Mar 20207:00 amRNSAnnual Financial Report
19th Feb 20207:00 amRNSDeath Of Director
15th Aug 20197:00 amRNSHalf-year Report
29th Mar 20197:00 amRNSAnnual Financial Report
15th Aug 20187:00 amRNSHalf-year Report
23rd Mar 20187:00 amRNSAnnual Financial Report
7th Aug 20177:00 amRNSHalf-year Report
29th Mar 20177:00 amRNSDirectorate Change
29th Mar 20177:00 amRNSAnnual Financial Report
3rd Aug 20167:00 amRNSDirectorate Change
3rd Aug 20167:00 amRNSHalf-year Report
17th Mar 20167:00 amRNSAnnual Financial Report
12th Aug 20157:00 amRNSHalf Yearly Report
27th May 20157:00 amRNSDirectorate Change
25th Mar 20157:00 amRNSAnnual Financial Report
27th Aug 20147:00 amRNSHalf Yearly Report
19th Mar 20147:00 amRNSFinal Results
27th Nov 20137:00 amRNSPROFIT WARNING
27th Aug 20137:00 amRNSHalf Yearly Report
2nd Apr 20137:00 amRNSDirectorate Change
2nd Apr 20137:00 amRNSAnnual Financial Report
30th Nov 20127:00 amRNSDirectorate Change
30th Nov 20127:00 amRNSProfit Warning Announcement
31st Aug 20127:00 amRNSInterim Financial Statements
22nd Aug 20127:00 amRNSDisposal
2nd Apr 20127:00 amRNSFinal results for the year ended 31 Dec 2011
7th Feb 20127:00 amRNSPublic Announcement
30th Aug 20117:11 amRNSHalf Yearly Report
18th Mar 20118:03 amRNSFinal Results 2010 Replacement
18th Mar 20117:39 amRNSFinal Results 2010
26th Jan 20117:00 amRNSPublic Announcement
25th Aug 20104:55 pmRNSHalf Yearly Report
12th Mar 20107:00 amRNSFinal Results
26th Aug 20097:00 amRNSHalf Yearly Report
5th Mar 20094:21 pmRNSFinal Results
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.